Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma
-
ナレーター：
-
著者：
Can a multi-metabolite blood test improve early pancreatic cancer detection? We spoke to Julia Mayerle about the METAPAC study, which sought to validate the ability of plasma metabolic signatures to find resectable tumors and reduce unnecessary invasive procedures in high-risk patients.
Read the full article:
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(25)00056-1/fulltext?dgcid=buzzsprout_icw_podcast_June_25_langas
Continue this conversation on social!
Follow us today at...
https://bsky.app/profile/lancetgastrohep.bsky.social
https://www.linkedin.com/company/langastro/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://youtube.com/thelancettv
The Lancet Gastroenterology & Hepatology in conversation with... is part of the Lancet Group podcast offering.
Editorial team: editor-in-chief Rob Brierley, deputy editor Aisling O'Brien, and senior editor Bethany Gomersall
Podcast editing: Matteo Simonetti
Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering.
Find the best science for better lives at https://www.thelancet.com/ Follow us today at... x.com/LancetGastroHep bsky.app/lancetgastrohep.bsky.social Linkedin.com Instagram Facebook youtube.com/thelancettv